Zacks Research Predicts Lower Earnings for Globus Medical

Globus Medical, Inc. (NYSE:GMED) – Equities researchers at Zacks Research decreased their Q2 2025 earnings per share estimates for shares of Globus Medical in a research note issued to investors on Thursday, May 29th. Zacks Research analyst R. Department now expects that the medical device company will post earnings of $0.79 per share for the quarter, down from their previous estimate of $0.85. The consensus estimate for Globus Medical’s current full-year earnings is $3.44 per share. Zacks Research also issued estimates for Globus Medical’s FY2025 earnings at $3.17 EPS, Q1 2026 earnings at $0.84 EPS, FY2026 earnings at $3.70 EPS, Q1 2027 earnings at $0.88 EPS and FY2027 earnings at $4.19 EPS.

A number of other equities research analysts have also recently commented on the stock. Truist Financial cut their price target on shares of Globus Medical from $80.00 to $68.00 and set a “hold” rating on the stock in a report on Monday, May 12th. Stifel Nicolaus raised their price target on Globus Medical from $92.00 to $94.00 and gave the stock a “buy” rating in a research note on Friday, February 21st. Piper Sandler reduced their price target on shares of Globus Medical from $100.00 to $80.00 and set an “overweight” rating for the company in a research report on Friday, May 9th. BTIG Research reiterated a “neutral” rating on shares of Globus Medical in a research note on Tuesday, May 27th. Finally, Barclays boosted their price objective on Globus Medical from $100.00 to $103.00 and gave the company an “overweight” rating in a research note on Monday, February 24th. Five analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat, Globus Medical presently has an average rating of “Moderate Buy” and an average price target of $94.00.

Globus Medical Stock Up 0.5%

Globus Medical stock opened at $59.18 on Monday. The stock’s 50 day moving average is $67.79 and its 200 day moving average is $77.98. Globus Medical has a twelve month low of $54.48 and a twelve month high of $94.93. The company has a market capitalization of $8.01 billion, a P/E ratio of 78.91, a PEG ratio of 1.61 and a beta of 1.32.

Globus Medical (NYSE:GMED) last issued its quarterly earnings results on Thursday, May 8th. The medical device company reported $0.68 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.74 by ($0.06). Globus Medical had a return on equity of 10.83% and a net margin of 4.09%. The business had revenue of $598.12 million during the quarter, compared to the consensus estimate of $629.74 million. During the same quarter in the previous year, the business earned $0.72 earnings per share. The firm’s revenue was down 1.4% compared to the same quarter last year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in GMED. Invesco Ltd. grew its stake in shares of Globus Medical by 331.9% in the 1st quarter. Invesco Ltd. now owns 2,021,156 shares of the medical device company’s stock worth $147,949,000 after buying an additional 1,553,154 shares in the last quarter. Norges Bank bought a new stake in shares of Globus Medical during the 4th quarter worth approximately $117,102,000. RTW Investments LP purchased a new position in Globus Medical during the 4th quarter valued at $80,394,000. Iron Triangle Partners LP bought a new position in shares of Globus Medical in the fourth quarter worth about $69,808,000. Finally, Polar Capital Holdings Plc bought a new position in Globus Medical in the 4th quarter worth about $63,762,000. Institutional investors own 95.16% of the company’s stock.

Globus Medical declared that its Board of Directors has approved a stock repurchase plan on Thursday, May 15th that permits the company to buyback $500.00 million in outstanding shares. This buyback authorization permits the medical device company to reacquire up to 6.3% of its stock through open market purchases. Stock buyback plans are typically an indication that the company’s management believes its stock is undervalued.

Globus Medical Company Profile

Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.